Stan przedcukrzycowy a możliwości farmakoterapii Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Piotr Sobieraj
Marta Kowalczyk
Krzysztof Dęmbe

Abstrakt

Nieprawidłowa glikemia na czczo oraz nieprawidłowa tolerancja glukozy, wspólnie określane jako stan przedcukrzycowy, są związane z istotnym ryzykiem rozwoju cukrzycy. Przeprowadzone ostatnio badania dotyczące interwencji polegającej na modyfikacji stylu życia (dieta oraz wysiłek fizyczny) udowodniły skuteczność leczenia niefarmakologicznego w zapobieganiu cukrzycy u chorych ze stanem przedcukrzycowym. W artykule przedstawiono kryteria rozpoznania, zasady diagnostyki, epidemiologię zaburzeń węglowodanowych w Polsce oraz dowody naukowe dotyczące skuteczności farmakoterapii u chorych ze stanem przedcukrzycowym.

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
Sobieraj , P., Kowalczyk , M., & Dęmbe , K. (2016). Stan przedcukrzycowy a możliwości farmakoterapii . Kardiologia W Praktyce, 10(3), 10-17. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1271
Dział
Artykuły

Bibliografia

1. Rutkowski M., Bandosz P., Czupryniak L. et al.: Prevalence of diabetes and impaired fasting glucose in Poland – the NATPOL 2011 Study. Diabet. Med. 2014; 31(12): 1568-1571.
2. International Diabetes Federation: IDF Diabetes Atlas – 7th Edition [online: http://www.diabetesatlasorg/across-the-globe.html].
3. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35(supl. 1): S64-S71.
4. Polskie Towarzystwo Diabetologiczne: Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2016. Diab. Klin. 2016; 5(supl. A).
5. World Health Organization (WHO) IC: Definition and diagnosis of diabetes and intermediate hyperglycaemia. Online: http://www.who.int/diabetes/publications/diagnosis_diabetes2006/en/.
6. Mastalerz-Migas A., Pokorna-Kalwak D., Sapilak B.: The use of FINDRISC questionnaire in assessment of risk of the type 2 diabetes development in patients with hypertension. Atherosclerosis 2014; 235(2): e279.
7. American Diabetes Association: 4. Prevention or Delay of Type 2 Diabetes. Diabetes Care 2016; 39(supl. 1): S36-S38.
8. Abdul-Ghani M., DeFronzo R.A., Jayyousi A.: Prediabetes and risk of diabetes and associated complications: impaired fasting glucose versus impaired glucose tolerance: does it matter? Curr. Opin. Clin. Nutr. Metab. Care 2016 Jul 6 [Epub ahead of print].
9. Diabetes Prevention Program Research Group: The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet. Med. 2007; 24(2): 137-144.
10. Cheng Y.J., Gregg E.W., Geiss L.S. et al.: Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds. Diabetes Care 2009; 32(11): 2027-2032.
11. Ziegler D., Rathmann W., Dickhaus T. et al.: Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008; 31(3): 464-469.
12. Decode Study Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26(3): 688-696.
13. Tuomilehto J., Lindstrom J., Eriksson J.G. et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001; 344(18): 1343-1350.
14. Penn L., White M., Oldroyd J. et al.: Prevention of type 2 diabetes in adults with impaired glucose tolerance: the European Diabetes Prevention RCT in Newcastle upon Tyne, UK. BMC Public Health 2009; 9: 342.
15. Roumen C., Corpeleijn E., Feskens E.J. et al.: Impact of 3-year lifestyle intervention on postprandial glucose metabolism: the SLIM study. Diabet. Med. 2008; 25(5): 597-605.
16. Knowler W.C., Barrett-Connor E., Fowler S.E. et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002; 346(6): 393-403.
17. Sussman J.B., Kent D.M., Nelson J.P., Hayward R.A.: Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ 2015; 350: h454.
18. Diabetes Prevention Program Research Group: Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003; 26(4): 977-980.
19. Perreault L., Pan Q., Mather K.J. et al.: Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012; 379(9833): 2243-2251.
20. Salpeter S.R., Buckley N.S., Kahn J.A., Salpeter E.E.: Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am. J. Med. 2008; 121(2): 149-157.e2.
21. Chiasson J.L., Josse R.G., Gomis R. et al.: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359(9323): 2072-2077.
22. Chiasson J.L.: Acarbose for type 2 diabetes prevention. Lancet 2002; 360(9344): 1517.
23. Scheen A.J.: Acarbose for type 2 diabetes prevention. Lancet 2002; 360(9344): 1516.
24. DeFronzo R.A., Tripathy D., Schwenke D.: Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 2011; 364: 1104-1115.
25. Espinoza S., Wang C., Tripathy D. et al.: Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose tolerance. GeroScience 2016; 38: 485.
26. Kernan W.N., Viscoli C.M., Furie K.L. et al.: Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N. Engl. J. Med. 2016; 374(14): 1321-1331.
27. Origin Trial Investigators: Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 2012; 367(4): 319-328.
28. Torgerson J.S., Hauptman J., Boldrin M.N., Sjostrom L.: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27(1): 155-161.
29. European Society of Cardiology: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur. Heart J. 2013; 34(39): 3035-3087.
30. NICE: Type 2 diabetes: prevention in people at high risk [online: www.nice.org.uk/guidance/ph38].
31. Alberti K.G., Zimmet P., Shaw J.: International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet. Med. 2007; 24(5): 451-463.